| Date | Title | Description |
| 21.08.2026 | Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results | Topline Data from Phase 2b Studies Inform HBV Functional Cure Strategy; Additional Data Expected in 2H 2026
Emerging Discovery Programs Build Momentum
BRII-5395 mRNA Cancer Vaccine Moving into Clinical Evaluation for HCC
Strong Cash Positio... |
| 03.07.2026 | Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B | End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure strategies
End-of-treatment data from ENHANCE did not d... |
| 27.05.2026 | Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV | - Final results from the ENSURE study demonstrate that the addition of elebsiran resulted in a higher functional cure rate compared with pegylated interferon alfa (PEG-IFNα) alone
- Data from Cohort 4 suggested that participants responding ... |
| 26.04.2026 | Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026 | - Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds |
| 19.03.2026 | Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results | Advancing HBV Functional Cure Toward Key Phase 2b Data Readouts
Increasing Discovery Efforts to Drive Long-term Value Creation
Strong Cash Position Supporting Strategic Priorities
Upcoming Conference Calls:
English Session: March 20 at 8:30... |
| 10.11.2025 | Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B | Cohort 4 follow-up confirms durable hepatitis B surface antigen (HBsAg) loss at 24 weeks post end of treatment (EOT) in BRII-179 anti-HBs responders treated with elebsiran plus pegylated interferon alfa (PEG-IFNα)
Data suggest the potential... |
| 07.11.2025 | Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine | Findings provide scientific insights into the contribution of small interfering RNA (siRNA) and therapeutic vaccination towards the HBV functional cure strategy
DURHAM, N.C. and BEIJING, Nov. 7, 2025 /PRNewswire/ -- Brii Biosciences Limited... |
| 21.08.2025 | Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results | Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy
Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic soralimixin
Strong Cash Position to Pursue New Discovery Opportunities an... |
| 04.07.2025 | Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China | Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China
Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other pri... |
| 08.05.2025 | Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss | End of treatment (EOT) data from Cohort 4 of the ENSURE study suggest that patients responding to prior BRII-179 treatment achieved faster and higher rate of surface antigen clearance with curative treatments compared to BRII-179 naïve part... |
| 01.04.2025 | Navigating Economic Currents: The IMF's Outlook Amid Tariff Turbulence | The global economy is a vast ocean, constantly shifting and swirling. In this unpredictable sea, the International Monetary Fund (IMF) serves as a lighthouse, guiding nations through storms of uncertainty. Recently, Kristalina Georgieva, th... |
| 30.03.2025 | Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification | Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and have the potential to achieve higher HBsAg loss at EOT
48-week EOT data from Coho... |
| 21.03.2025 | Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results | Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure
Data from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio's HBV Functional... |
| 31.12.2024 | Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study | Further secures Brii's rights in BRII-179 with full control of intellectual property, future manufacturing and supply
Several combination treatment studies containing BRII-179 have quickly started to carry forward the Company's strategy for... |
| 20.11.2024 | A New Dawn in Hepatitis B Treatment: Brii Bio's Breakthrough Study | In the world of medicine, hope often springs from the most unexpected places. Brii Biosciences Limited, a biotechnology company, has recently unveiled promising results from its Phase 2 ENSURE study, showcasing a potential game-changer in t... |
| 19.11.2024 | Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen... | 48-week end-of-treatment data from the ongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFNα
Data from multiple combination studies spo... |
| 07.06.2024 | Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024 | New translational data demonstrate that BRII-179-induced immune responses are associated with high HBsAg reduction in a subset of participants with chronic HBV infection
BRII-179 as add-on therapy induces functional antibody responses and c... |
| 14.05.2024 | Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies | DURHAM, N.C. and BEIJING, May 14, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across... |
| 22.03.2024 | Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results | Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy
Integrating R&D, manufacturing and commercial upsides by acquiring fu... |
| 18.03.2024 | Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer | SHANGHAI, March 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovativ... |
| 14.02.2024 | Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies | Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and royalty payments to VBI, subject to achievement of certain activities
Transferring manufacturing technologies of BRII-179 and PreHevbrio/PreHevb... |
| 03.01.2024 | Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer | DURHAM, N.C., and BEIJING, Jan. 3, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice acros... |
| 14.11.2023 | Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023 | Direct evidence that BRII-179-induced functional antibody responses can contribute to increased and sustained HBsAg loss rate
New insight in utilizing BRII-179 to enriching patients with intrinsic humoral immune responses for higher HBsAg l... |
| 06.09.2023 | Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B | BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at the end of treatment and 12 weeks follow up
Significantly increased HBsAg seroconversion rate is strongly associated with BRII-179 treatment ... |
| 22.08.2023 | Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results | First patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure
First of several studies to investigate the potential of BRII-179 in enriching patients with strong intrinsic anti-HBsAg re... |
| 06.07.2023 | Brii Biosciences Provides Latest Clinical Development and Corporate Updates | Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets
New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at ... |
| 06.07.2023 | Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure | Extension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to achieve best-in-class HBV functional cure in broad patient populations
Company also acquires exclusive rights to PreHevbri®, a clinically diffe... |
| 26.06.2023 | Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693 | Company acquires exclusive global rights of the novel lipopeptide BRII-693 for the difficult to treat MDR/XDR gram-negative bacterial infections
Company returns Greater China rights to Qpex Biopharma of beta-lactamase inhibitor QPX7728-base... |
| 25.06.2023 | Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023 | Late-breaking data from BRII-835 + PEG-IFN-a study demonstrate anti-HBs titers at the end of treatment were associated with sustained HBsAg loss 24 weeks after the end of treatment
New data show more robust and persistent anti-HBs titers fo... |
| 01.06.2023 | Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders | BRII-297, a first-of-its-kind treatment option for anxiety and depressive disorders, has the potential to enable greater therapeutic adherence and convenience for patients
DURHAM, N.C. and BEIJING, June 1, 2023 /PRNewswire/ -- Brii Bioscien... |
| 28.04.2023 | Brii Bio Publishes 2022 Environmental, Social and Governance Report | Brii Bio receives an "A" grade in the latest MSCI ESG Rating
DURHAM, N.C. and BEIJING, April 28, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company," stock code: 2137.HK), a biotechnology... |
| 24.03.2023 | Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results | Company maintains priority focus on clinical programs to develop a novel functional cure for hepatitis B viral (HBV) infection and a potential first-of-its-kind treatment for postpartum depression (PPD) and major depressive disorders (MDD)
... |
| 24.03.2023 | Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results | Company maintains priority focus on clinical programs to develop a novel functional cure for hepatitis B viral (HBV) infection and a potential first-of-its-kind treatment for postpartum depression (PPD) and major depressive disorders (MDD)
... |
| 27.12.2022 | Brii Biosciences Provides Update on Strategic Clinical Development Progress | Topline Phase 2 data from multiple hepatitis B viral (HBV) infection functional cure combination studies expected in the first half of 2023
Initiation of Phase 2 postpartum depression (PPD) study planned for early 2023 to advance potential ... |
| 27.12.2022 | Brii Biosciences Provides Update on Strategic Clinical Development Progress | Topline Phase 2 data from multiple hepatitis B viral (HBV) infection functional cure combination studies expected in the first half of 2023
Initiation of Phase 2 postpartum depression (PPD) study planned for early 2023 to advance potential ... |
| 19.10.2022 | Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022 | Findings from two Phase 1 studies show both BRII-732 and BRII-778 are safe and well-tolerated
Results indicate potential for oral once-weekly, long-acting combination therapy for HIV infection, supporting continued clinical development
Addi... |
| 26.09.2022 | Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression | Data demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable pharmacokinetic profile and is safe and well-tolerated in healthy subjects
Findings suggest BRII-296 has potential to provide a safe and effective, o... |
| 01.09.2022 | Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum | Addition increases diversity of Board governance and supports further independent expertise
DURHAM, N.C. and BEIJING, Sept. 1, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.... |
| 24.08.2022 | Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results | Additions to executive team strengthen global leadership and position Company for strategic long-term growth
First-ever product launch of long-acting amubarvimab/romlusevimab combination therapy for COVID-19 in China advances Brii Bio from ... |
| 23.08.2022 | Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head | Building a leadership team with global and local experience and expertise to enable rapid execution across Company's broad therapeutic strategy
DURHAM, N.C. and BEIJING, Aug. 23, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio... |
| 27.07.2022 | Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron ... | Independent lab results demonstrate that the combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously demonstrated with all variants of concern to date
The amubarvimab/romlusevimab combina... |
| 19.07.2022 | Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlus... | The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 tar... |
| 13.07.2022 | Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer | Strategic executive hire adds to Company's global leadership team and positions the Company for continued growth
DURHAM, N.C.and BEIJING, July 13, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company"... |
| 07.07.2022 | Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China | The Company is working closely with its commercial partners to supply the combination therapy to patients in need
Brii Bio progressed the combination therapy from discovery to global Phase 3 data readout and first regulatory approval by the... |
| 04.07.2022 | Brii Biosciences Exercises Option for Vir Biotechnology's VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China | Exclusive development and commercialization rights to VIR-3434 in China strengthen Company's leadership and robust clinical pipeline in HBV
Key partnership with Vir enables multitude of combination treatment options as part of Company's str... |
| 09.06.2022 | Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China | Data are consistent with the results of the global Phase 3 ACTIV-2 trial, demonstrating a favorable safety and tolerability profile in people with both severe and non-severe SARS-CoV-2 infections in China
Clinical benefits were observed in ... |
| 25.05.2022 | Brii Biosciences to be Added to MSCI China Small Cap Index | DURHAM, N.C. and BEIJING, May 25, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) today announced that it will be added to the MSCI China Small Cap Index, effective as of ... |
| 09.05.2022 | Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvaria... | Studies conducted by independent labs demonstrate the amubarvimab/romlusevimab combination retains neutralizing activity against COVID-19 Omicron variant
Review of the monoclonal antibody combination therapy is underway by the U.S. Food and... |
| 07.05.2022 | Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report | DURHAM, N.C. and BEIJING, May 7, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company," stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant un... |
| 31.03.2022 | Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022 | New data demonstrate BRII-835 (VIR-2218) was well tolerated with notable reductions in serum HBsAg observed in the Chinese patients infected with chronic hepatitis B
DURHAM, N.C. and BEIJING, March 31, 2022 /PRNewswire/ -- Brii Biosciences ... |
| 30.03.2022 | Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China | DURHAM, N.C. and BEIJING, March 30, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant ... |
| 23.03.2022 | Brii Biosciences Provides Corporate Update and Reports Full Year 2021 Financial Results | – Advancing key programs in HBV, CNS, and HIV –
– Received first BLA approval for COVID-19 Treatment in China and added to China's latest COVID-19 Diagnosis and Treatment Guidelines–
– Multiple clinical value drivers expected across the por... |
| 16.03.2022 | Brii Bio Announces that National Health Commission of China Adds Amubarvimab/Romlusevimab Combination to its COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition) | The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 target-specific treatment in China, through a randomized, double-blind and placebo-controlled trial
In vitro tests shows that amubarvimab/romlu... |
| 27.01.2022 | Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources | DURHAM, N.C. and BEIJING, Jan. 27, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant u... |
| 27.12.2021 | Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B | DURHAM, N.C. and BEIJING, Dec. 27, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant u... |
| 12.12.2021 | Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant | DURHAM, N.C. and BEIJING, Dec. 12, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant ... |
| 12.12.2021 | Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant | DURHAM, N.C. and BEIJING, Dec. 12, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant ... |
| 09.12.2021 | Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China | The approval marks the first locally-discovered and approved SARS-CoV-2 target-specific treatment in China, through a randomized, double-blind and placebo-controlled trial
Brii Bio is also seeking U.S. FDA Emergency Use Authorization for th... |
| 09.12.2021 | Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China | The approval marks the first locally-discovered and approved SARS-CoV-2 target-specific treatment in China, through a randomized, double-blind and placebo-controlled trial
Brii Bio is also seeking U.S. FDA Emergency Use Authorization for th... |
| 06.12.2021 | Brii Biosciences Included in Hong Kong Stock Connect | DURHAM, N.C. and BEIJING, Dec. 6, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), today announced that the Company has been added to the Hong Kong Stock Connect. This inc... |
| 06.12.2021 | Brii Biosciences Included in Hong Kong Stock Connect | DURHAM, N.C. and BEIJING, Dec. 5, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), today announced that the Company has been added to the Hong Kong Stock Connect. This inc... |
| 19.11.2021 | Brii Biosciences Joins Hang Seng Composite Index | DURHAM, N.C. and BEIJING, Nov. 19, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), today announced that Brii Biosciences has been included as a constituent stock of the H... |
| 19.11.2021 | Brii Biosciences Joins Hang Seng Composite Index | DURHAM, N.C. and BEIJING, Nov. 19, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), today announced that Brii Biosciences has been included as a constituent stock of the H... |
| 17.11.2021 | Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit | BEIJING and DURHAM, N.C., Nov. 17, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant u... |
| 17.11.2021 | Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit | BEIJING and DURHAM, N.C., Nov. 17, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant u... |
| 09.10.2021 | Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk o... | DURHAM, N.C. and BEIJING, Oct. 9, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant un... |
| 04.10.2021 | Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company's SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021 | DURHAM, N.C.and BEIJING, Oct. 4, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unm... |
| 28.09.2021 | Brii Biosciences : Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy | DURHAM, N.C. and BEIJING, Sept. 27, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant ... |
| 28.09.2021 | Brii Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy | DURHAM, N.C. and BEIJING, Sept. 28, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant ... |
| 07.09.2021 | Brii Biosciences Adds US$100 Million to Advance its Late-Stage Monoclonal Antibody Combination Therapy, BRII-196/BRII-198, for Non-Hospitalized COVID-19 Patients | DURHAM, N.C. and BEIJING, Sept. 7, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant u... |
| 25.08.2021 | Brii Biosciences : Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients | DURHAM, N.C. and BEIJING, Aug. 24, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant u... |
| 25.08.2021 | Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients | DURHAM, N.C. and BEIJING, Aug. 25, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant u... |
| 05.08.2021 | Brii Biosciences Announces the Completion of Enrollment in the Phase 3 National Institutes of Health (NIH) ACTIV-2 Trial, Evaluating the BRII-196 and BRII-198 Monoclonal Neutralizing Antibody Combinat... | 846 outpatients at high risk of clinical progression have been enrolled in the ACTIV-2 phase 2/3 clinical study, from sites in the United States, Brazil, South Africa, Mexico and Argentina.
The participants are being evaluated for the combi... |
| 05.08.2021 | Brii Biosciences : Announces the Completion of Enrollment in the Phase 3 National Institutes of Health (NIH) ACTIV-2 Trial, Evaluating the BRII-196 and BRII-198 Monoclonal Neutralizing Antibody Combin... | 846 outpatients at high risk of clinical progression have been enrolled in the ACTIV-2 phase 2/3 clinical study, from sites in the United States, Brazil, South Africa, Mexico and Argentina.
The participants are being evaluated for the combi... |
| 13.07.2021 | Baptized by Covid-19 fire, Brii Bio reaps $320M Hong Kong IPO to carry on with pipeline for infectious diseases and beyond | Zhi Hong started Brii Bio three years ago with the clear vision that his trans-Pacific startup should have the best of both worlds — top-notch innovation from the US, vast patient pool and market in China — tethered by his years... |
| 13.07.2021 | Baptized by Covid-19 fire, Brii Bio reaps $320M Hong Kong IPO to carry on with pipeline for infectious diseases and beyond | Venture capitalist Bob Nelsen was sitting on his couch two summers ago when he got a call from a famous scientist, who matter-of-factly explained that he had developed a potentially groundbreaking technology but that he couldn’t give any de... |
| 13.07.2021 | Baptized by Covid-19 fire, Brii Bio reaps $320M Hong Kong IPO to carry on with pipeline for infectious diseases and beyond | When Bruce Booth helped launch Nimbus Therapeutics back in 2009, it was difficult to find co-investors willing to back the company’s pioneering computational chemistry platform. Those were the “leaner times for the sector,” he said, and the... |
| 02.07.2021 | Busy IPO week winds down as two more biotechs — and one looking to improve clinical trials — file for public debuts | Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
Two more biotech companies — and one that’s committed to supporting clinical research — filed for IPOs jus... |
| 20.04.2021 | BRII scheme: $10 million in grant funding up for grabs for regtech innovation | The federal government has committed $10 million in grant funding for regtech companies creating innovative solutions to a set of key challenges.
Under the latest round of the Business Research and Innovation Initiative (BRII), Australian s... |
| 25.03.2021 | Jack Ma, Sequoia China-backed biotech firm Brii Bio raises $155m in Series C round | Premium
Brii Biosciences (Brii Bio), a multi-national innovative therapies developer with operations in both China and the US, has raised $155 million in a Series C round of financing ahead of a potential listing in Hong Kong.
Continue read... |
| 25.03.2021 | Jack Ma, Sequoia China-backed biotech firm Brii Bio raises $155m in Series C round | Brii Biosciences (Brii Bio), a multi-national innovative therapies developer with operations in both China and the US, has raised $155 million in a Series C round of financing ahead of a potential listing in Hong Kong.
The new financing was... |
| 24.03.2021 | Brii Biosciences Closes US$155M Series C Financing | Brii Biosciences, a Durham, NC- and Beijing, China-based multi-national company developing innovative therapies for diseases including infectious diseases, liver diseases, and CNS diseases, closed a Series C financing of US$155m.
The round ... |
| 23.03.2021 | Brii Biosciences Closes US$155 Million Series C Financing | – Financing led by Invesco Developing Markets Fund, joined by a syndicate of new and current investors
– Proceeds will support accelerating clinical development programs in the United States and China
DURHAM, N.C. & BEIJING–(BUSINESS WI... |
| 23.03.2021 | Brii Biosciences Closes US$155 Million Series C Financing | DURHAM, N.C. & BEIJING--(BUSINESS WIRE)--Mar 23, 2021--
Brii Biosciences (“Brii Bio”), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burden, today anno... |
| 04.03.2021 | Brii Biosciences Antibody Combination Will Not Progress into a Phase 3 Study Evaluating the Treatment of SARS-CoV-2 in Hospitalized Patients | DURHAM, N.C. & BEIJING--(BUSINESS WIRE)--Mar 4, 2021--
Brii Biosciences (“Brii Bio”), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and with a high public health impact, today... |
| 01.09.2020 | STAT China: Lineup for Hong Kong IPO grows, and a conversation with Junshi’s Li Ning | A version of this digest first appeared in the weekly STAT China newsletter. To receive future editions, sign up here.
Happy Tuesday and welcome back to STAT China. The CEO of Junshi Biosciences joins us for our latest “newsmaker” interview... |
| 02.04.2020 | ARCH Venture, Flagship Pioneering close funds worth nearly $2.6B | ARCH said it would use its two funds to invest in early-stage companies. Although it plans to frequently draw from both to invest in a single company, the overage fund will be used in fewer deals that require larger investments.
“ARCH is st... |
| 25.05.2018 | Brii Biosciences Debuts With China Public Health Strategy and USD260 Mln Financing Backed by Alibaba | (Yicai Global) May 25 -- Brii Biosciences, a Chinese biomedical startup, has been unveiled with significant partnerships and USD260 million financing, which it will spend on the research and development of infectious disease drugs to help e... |
| 25.05.2018 | Term Sheet — Friday, May 25 | THE PET WARS
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
UP AGAINST SOFTBANK: Rover, the pet-sitting and pet-walking company, is raising $125 million in funding, along with $30 million of... |
| 24.05.2018 | Brii Bio Raises $260M in Initial Funding | Brii Bio, a company committed to serving patients’ needs and improving public health in China, raised $260M in funding.
Backers included ARCH Venture Partners, 6 Dimensions Capital, Boyu Capital, Yunfeng Capital, Sequoia Capital, and Blue P... |
| 24.05.2018 | Brii Biosciences Raises $260M | Brii Bio, a company committed to serving patients' needs and improving public health in China, today announced its launch with significant partnerships and financing.
Brii Bio aims to accelerate the development and delivery of breakthrough ... |
| 24.05.2018 | Brii Biosciences Launches to Bring Innovative Medicines to Chinese Patients | - |
| 24.05.2018 | Brii Biosciences Raises $260M | Brii Bio, a company committed to serving patients' needs and improving public health in China, today announced its launch with significant partnerships and financing.
Brii Bio aims to accelerate the development and delivery of breakthrough ... |
| - | ARCH Venture, Flagship Pioneering close funds worth nearly $2.6B | Two large venture capital firms have raised nearly $2.6 billion that they plan to invest in life sciences startups, they said in announcements Thursday.
Cambridge, Massachusetts-based Flagship Pioneering said it had closed a $1.1 billion ca... |
